Bayer’s asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over…